Mytos Brings Robotic Scale to Human Cell Manufacturing, Targeting a 1,000x Capacity Gap

Mytos, a London-based biotech automation startup, is building robotic platforms that manufacture human cells at an industrial scale, turning pluripotent stem cells into specialised cells like neurons and cardiomyocytes over multi-week protocols with minimal human touch.

The company says fully automated cell production is the missing link to scaling regenerative medicine from breakthrough case studies to routine care.

Founded by CEO Ali Afshar and co-founder Ignacio Willats, Mytos sits at the nexus of hardware, IoT, and biotechnology. The team’s platform automates cell culture, differentiation, and quality control, promising repeatability and GMP-friendly workflows.

According to the company, the need is urgent: in the past year, patients have seen functional cures for Parkinson’s disease, vision loss, and Type 1 diabetes using stem-cell–derived cells—but global manufacturing capacity remains the bottleneck. Today’s hand-crafted processes are labour-intensive, expensive, and inherently limited in throughput. Mytos claims its automation can unlock the 1,000x capacity increase required to serve millions of patients.

The company has secured its first commercial manufacturing deal to supply neurons for Parkinson’s programs and is in active discussions with a majority of top players in the field. While terms were not disclosed, this early traction positions Mytos within the emerging CDMO-like landscape for cell therapies, where reliability, cost-per-dose, and lot consistency are critical benchmarks.

Industry comparables include closed-system bioprocessing and robotic culture suites; Mytos differentiates on end-to-end automation tuned specifically for stem-cell differentiation rather than just expansion.

The addressable market is expanding rapidly. Regenerative medicine funding has surged alongside clinical milestones in iPSC- and ESC-derived therapies, yet developers face acute COGS and staffing constraints. Key growth drivers for Mytos include: GMP-grade scalability, higher batch success rates, reduced operator variability, and software-defined protocols that shorten tech transfer timelines. If validated at scale, these factors can materially lower cost per cell and accelerate time-to-clinic for partners.

Early users include biotech developers advancing neuron, RPE, beta cell, and cardiomyocyte programs; over time, Mytos could power broader applications across toxicology testing, disease modelling, and precision manufacturing for allogeneic therapies.

The company’s strategic positioning—as the automation backbone for stem-cell–derived products—aligns with a market shift from bespoke processes to standardised, software-driven manufacturing.

With automated runs already in place and commercial conversations underway, Mytos is emerging as a pivotal enabler for the next wave of regenerative medicine—moving cell manufacturing from artisanal to industrial, and bringing curative therapies within reach of scale.

More at https://www.mytos.bio.